BackgroundCheck.run
Search For

Jeffrey W Hewett, 58765 Union St, Duxbury, MA 02332

Known as:
Jeff W Hewett Jeff C Hewett Jeffery W Hewett Jeffrey W Hewitt
Related to:
Maura A Smith 42

Jeffrey Hewett Phones & Addresses

765 Union St, Duxbury, MA 02332    781-8378415   

Randolph, MA   

Work

Position: Food Preparation and Serving Related Occupations

Education

Degree: Bachelor's degree or higher
Get Report
Control this profile

Mentions for Jeffrey W Hewett

Jeffrey Hewett resumes & CV records

Resumes

Jeffrey Hewett Photo 23

Jeffrey Hewett

Jeffrey Hewett Photo 24

Jeffrey Hewett

Publications & IP owners

Us Patents

Secreted Luciferase Fluorescent Protein Conjugate Nucleic Acid Construct And Uses Thereof

US Patent:
2010003, Feb 11, 2010
Filed:
Oct 12, 2007
Appl. No.:
12/444068
Inventors:
Bakhos A. Tannous - Malden MA, US
Xandra Breakefield - Newton MA, US
Jeffrey W. Hewett - Duxbury MA, US
Assignee:
THE GENERAL HOSPITAL CORPORATION - Boston MA
International Classification:
C12Q 1/66
C07H 21/00
US Classification:
435 8, 536 232
Abstract:
The present invention relates generally to methods to monitor the transport of proteins through the secretory pathway, and methods to monitor ER stress. In particular, the present invention relates to methods to monitor, in real-time, the processing of protein through the secretory pathway, which can be monitored both at a subcellular level by florescence visualization and quantitatively by detecting the secreted luciferase reporter protein. The present invention also relates to methods to assess biological processes in cells, in particular the secretory pathway and ER stress, as well as methods to identify agents which augment or inhibit the secretory pathway and/or ER stress. The present invention also relates to compositions and nucleic constructs encoding a secreted luciferase-fluorescent protein conjugate for methods to monitor protein trafficking in the cell by simultaneous detection of fluorescence and luciferase secretion.

Diagnostic Biomarkers For Fibrotic Disorders

US Patent:
2012018, Jul 19, 2012
Filed:
May 7, 2010
Appl. No.:
13/319133
Inventors:
Alan Buckler - Arlington MA, US
Chao-Min Chen - Belmont MA, US
Chantale T. Guy - Medford MA, US
Jeffrey Hewett - Duxbury MA, US
Assignee:
NOVARTIS AG - Basel
International Classification:
A61K 39/395
A61K 31/7088
A61K 38/02
A61K 31/7105
C12Q 1/68
C40B 30/04
G01N 33/566
A61P 9/00
A61P 11/00
A61P 1/18
A61P 1/16
A61P 13/12
A61P 21/00
A61P 17/00
A61P 27/02
A61P 27/06
A61P 43/00
A61P 37/06
A61P 13/00
A61P 35/00
C12N 5/071
US Classification:
4241341, 435375, 4241581, 514 44 R, 514 88, 4241331, 4241361, 4241351, 514 44 A, 4241781, 435377, 435 612, 506 9, 436501, 435 79, 435 71, 4241451
Abstract:
The present invention provides novel methods of inhibiting fibrosis, as well as methods of treating or inhibiting fibrotic disorders, using BMP9 and/or BMP10 antagonists. The present invention also provides methods of assessing whether a subject has or is at risk of developing a fibrotic disorder by detecting levels of BMP9 and/or BMP10. Further provided are methods of assessing the efficacy of a treatment regimen for treating a fibrotic disorder by detecting and comparing pre-treatment levels of BMP9 and BMP10 with post-treatment levels of BMP9 and BMP10.

Diagnostic Biomarkers For Fibrotic Disorders

US Patent:
2013020, Aug 15, 2013
Filed:
Mar 28, 2013
Appl. No.:
13/852079
Inventors:
Alan Buckler - Arlington MA, US
Chao-Min Chen - Shanghai, CN
Chantale T. Guy - Medford MA, US
Jeffrey Hewett - Duxbury MA, US
Chris Lu - Shanghai, CN
Jing Wu - Shanghai, CN
International Classification:
A61K 38/18
A61K 38/16
A61K 31/7088
A61K 45/06
A61K 39/395
G01N 33/50
US Classification:
4241581, 435 61, 435 71, 435 79, 435375, 514 88, 514 44 R
Abstract:
The present invention provides novel methods of inhibiting fibrosis, as well as methods of treating or inhibiting fibrotic disorders, using BMP9 and/or BMP10 antagonists. The present invention also provides methods of assessing whether a subject has or is at risk of developing a fibrotic disorder by detecting levels of BMP9 and/or BMP10. Further provided are methods of assessing the efficacy of a treatment regimen for treating a fibrotic disorder by detecting and comparing pre-treatment levels of BMP9 and BMP10 with post-treatment levels of BMP9 and BMP10.

Diagnostic Biomarkers For Fibrotic Disorders

US Patent:
2018028, Oct 4, 2018
Filed:
Jun 8, 2018
Appl. No.:
16/003394
Inventors:
- Basel, CH
Chao-Min Chen - Cambridge MA, US
Chantale T. Guy - Medford MA, US
Jeffrey Hewett - Duxbury MA, US
Chris Xiangyang Lu - Lexington MA, US
Jing Wu - Hangzhou Zhejiang, CN
Assignee:
NOVARTIS AG - Basel
International Classification:
A61K 38/18
A61K 45/06
G01N 33/50
G01N 33/74
A61K 39/395
A61K 38/16
A61K 31/7088
Abstract:
The present invention provides novel methods of inhibiting fibrosis, as well as methods of treating or inhibiting fibrotic disorders, using BMP9 and/or BMP10 antagonists. The present invention also provides methods of assessing whether a subject has or is at risk of developing a fibrotic disorder by detecting levels of BMP9 and/or BMP10. Further provided are methods of assessing the efficacy of a treatment regimen for treating a fibrotic disorder by detecting and comparing pre-treatment levels of BMP9 and BMP10 with post-treatment levels of BMP9 and BMP10.

Possible Relatives

Cynthia S Hewett  David Hewett  Dawn Hewett  Dagmar S Hewett  Daniel B Hewett  Aaron D Hewett  Danny E Hewett  Jeffrey P Johnson  Jeffrey Stamps  Jeffrey Standard 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.